来源:药渡撰文:Pharmadeep编辑:维他命2026年3月3日,国家药品监督管理局药品审评中心官网(CDE)公示,诺和诺德旗下重磅药物司美格鲁肽注射液的新适应症上市申请已获受理,并拟纳入优先审评。根据公示信息,此次申报的适应症为治疗代谢相关脂肪性肝炎(MASH)伴中重度肝纤维化的非肝硬化成人患者。继2025年8月在美国获批后,这款全球首个也是目前唯一获批用于治疗MASH的GLP-1类药物,正...
Source Link来源:药渡撰文:Pharmadeep编辑:维他命2026年3月3日,国家药品监督管理局药品审评中心官网(CDE)公示,诺和诺德旗下重磅药物司美格鲁肽注射液的新适应症上市申请已获受理,并拟纳入优先审评。根据公示信息,此次申报的适应症为治疗代谢相关脂肪性肝炎(MASH)伴中重度肝纤维化的非肝硬化成人患者。继2025年8月在美国获批后,这款全球首个也是目前唯一获批用于治疗MASH的GLP-1类药物,正...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.